期刊文献+

利格列汀治疗老年2型糖尿病患者的效果 被引量:1

下载PDF
导出
摘要 目的研究利格列汀治疗老年2型糖尿病患者的临床效果。方法选取2016年10月至2017年10月收治的90例老年2型糖尿病患者,随机分为试验组和对照组,各45例。对照组采用二甲双胍治疗,试验组在对照组治疗基础上加用利格列汀治疗。比较两组血糖、血脂、不良反应。结果与对照组相比,试验组空腹血糖(FPG)、餐后2 h血糖(2h PG)较低,差异有统计学意义(P<0.05);与对照组相比,试验组低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)、总胆固醇(TC)较低,差异有统计学意义(P<0.05);与对照组相比,试验组高密度脂蛋白胆固醇(HDL-C)较高,差异有统计学意义(P<0.05);与对照组相比,试验组不良反应发生率较低,差异有统计学意义(P<0.05)。结论利格列汀可有效控制2型糖尿病患者的血脂与血糖,减少不良反应,安全可靠。
作者 田增奎
机构地区 天津市河西医院
出处 《医疗装备》 2018年第7期91-93,共3页 Medical Equipment
  • 相关文献

参考文献8

二级参考文献82

  • 1Higgins JPT, Green S(editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 updated March 2011[OL].Cochrane website, www.cochrane-handbook.org. 2012-11-27/2012- 12-10.
  • 2Barnett AH, Patel S, Harper R, et al. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase Ⅲ trial with a 34-week active-controlled extension [J]. Diabetes Obes Metab, 2012,.
  • 3Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial [J]. Diabetes Obes Metab, 2011, 13(3): 258-267.
  • 4Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin(BI 1356), a potent and selective DPP-4 inhibitor, is safe and etticacious in combination with metformin in patients with inadequately controlled Type 2 diabetes [J]. Diabet Meal, 2010, 27(12): 1409-1419.
  • 5Gomis R, Espadero R M, Jones R, et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study [J]. Diabetes Obes Metab, 2011, 13(7): 653-661.
  • 6Haak T, Meinicke T, Jones R, et al. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study [J]. Diabetes Obes Metab, 2012, 14(6): 565-574.
  • 7Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy provides superior glyeaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: arandomized, placebo and active comparator-controlled, double-blind study [J]. Diabetes Obes Metab, 2012, 14(4): 348-357.
  • 8Lewin AJ, Arvay L, Liu D, et al. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial [J]. Clin Ther, 2012, 34(9): 1909-1919 el915.
  • 9Owens DR, Swallow R, Dugi KA, et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study [J]. Diabet Med, 2011, 28(11): 1352-1361.
  • 10Ross S A, Rafeiro E, Meinicke T, et al. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial [J]. Curr Med Res Opin, 2012, 28(9): 1465-1474.

共引文献53

同被引文献10

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部